Article

FDA clears online visual acuity test

Author(s):

The FDA describes the test as a web-based, self-guided software application that consumers can access using a touchscreen mobile device and internet-connected computer.

The FDA has cleared an online visual acuity test, the Visibly Digital Acuity Product (Visibly Inc.), for use.1

The FDA describes it as a web-based, self-guided software application that consumers can access using a touchscreen mobile device and internet-connected computer.

Adults aged 22 to 40 years who can perform an in-home self-test can use the test to help evaluate visual acuity, the FDA said.

“The application’s recommendations are intended to be supportive recommendations that will be used by an eye care provider, along with the patient’s medical history and profile, prior corrective eyewear prescriptions, and subjective vision data,” according to the FDA website. “This device does not provide screening or diagnosis of eye health or other disease and does not replace an eye health exam with a licensed provider.”

After the patient completes the test, the vision results are sent eye care professionals to evaluate and follow-up with the patient, for corrective lens prescription renewal online or referral for an in-person eye examination.

Reference

1. Larkin H. JAMA. Online visual acuity test cleared. 2022;328(13):1290. doi:10.1001/jama.2022.15443

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.